U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

APOLIPOPROTEIN A-I (MILANO)

MedGen UID:
864267
•Concept ID:
C4015830
•
Finding
OMIM®: 107680

Professional guidelines

PubMed

Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases.
Calabresi L, Sirtori CR, Paoletti R, Franceschini G
Curr Atheroscler Rep 2006 Mar;8(2):163-7. doi: 10.1007/s11883-006-0054-4. PMID: 16510051

Recent clinical studies

Etiology

Microarray analysis identifies human apoA-I(Milano) and apoA-II as determinants of the liver gene expression related to lipid and energy metabolism.
Ganzetti GS, Parolini C
Exp Cell Res 2023 Dec 1;433(1):113826. Epub 2023 Oct 18 doi: 10.1016/j.yexcr.2023.113826. PMID: 37858836
Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials.
Kühnast S, Fiocco M, van der Hoorn JW, Princen HM, Jukema JW
Eur J Pharmacol 2015 Sep 15;763(Pt A):48-63. Epub 2015 May 16 doi: 10.1016/j.ejphar.2015.03.089. PMID: 25989133
ETC-216 for coronary artery disease.
Nicholls SJ, Uno K, Kataoka Y, Nissen SE
Expert Opin Biol Ther 2011 Mar;11(3):387-94. Epub 2011 Jan 28 doi: 10.1517/14712598.2011.557061. PMID: 21271950
Structural and dynamic features of apolipoprotein A-I cysteine mutants, Milano and Paris, in synthetic HDL.
Rocco AG, Sensi C, Gianazza E, Calabresi L, Franceschini G, Sirtori CR, Eberini I
J Mol Graph Model 2010 Nov;29(3):406-14. Epub 2010 Aug 20 doi: 10.1016/j.jmgm.2010.08.002. PMID: 20869895
Recombinant apolipoprotein A-I(Milano): a novel agent for the induction of regression of atherosclerotic plaques.
Chiesa G, Sirtori CR
Ann Med 2003;35(4):267-73. doi: 10.1080/07853890310005281. PMID: 12846269

Diagnosis

A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux.
Favari E, Gomaraschi M, Zanotti I, Bernini F, Lee-Rueckert M, Kovanen PT, Sirtori CR, Franceschini G, Calabresi L
J Biol Chem 2007 Feb 23;282(8):5125-32. Epub 2006 Dec 12 doi: 10.1074/jbc.M609336200. PMID: 17164237
A model structure for the heterodimer apoA-IMilano-apoA-II supports its peculiar susceptibility to proteolysis.
Rocco AG, Mollica L, Gianazza E, Calabresi L, Franceschini G, Sirtori CR, Eberini I
Biophys J 2006 Oct 15;91(8):3043-9. Epub 2006 Aug 4 doi: 10.1529/biophysj.106.085886. PMID: 16891368Free PMC Article
Limited proteolysis of a disulfide-linked apoA-I dimer in reconstituted HDL.
Calabresi L, Tedeschi G, Treu C, Ronchi S, Galbiati D, Airoldi S, Sirtori CR, Marcel Y, Franceschini G
J Lipid Res 2001 Jun;42(6):935-42. PMID: 11369801
Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study.
Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, Salvetti M, Monteduro C, Zulli R, Muiesan ML, Agabiti-Rosei E
Circulation 2001 Apr 17;103(15):1949-54. doi: 10.1161/01.cir.103.15.1949. PMID: 11306522
Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer.
Calabresi L, Canavesi M, Bernini F, Franceschini G
Biochemistry 1999 Dec 7;38(49):16307-14. doi: 10.1021/bi991246n. PMID: 10587455

Therapy

A Compendium of the Biological Effects of Apolipoprotein A-I(Milano).
Parolini C
J Pharmacol Exp Ther 2020 Jan;372(1):54-62. Epub 2019 Oct 24 doi: 10.1124/jpet.119.261719. PMID: 31649050
ETC-216 for coronary artery disease.
Nicholls SJ, Uno K, Kataoka Y, Nissen SE
Expert Opin Biol Ther 2011 Mar;11(3):387-94. Epub 2011 Jan 28 doi: 10.1517/14712598.2011.557061. PMID: 21271950
Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention.
Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM
Nat Clin Pract Cardiovasc Med 2006 Oct;3(10):540-7. doi: 10.1038/ncpcardio0661. PMID: 16990839
ApoA-I Milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progression.
Kaul S, Shah PK
Curr Drug Targets Cardiovasc Haematol Disord 2005 Dec;5(6):471-9. doi: 10.2174/156800605774962004. PMID: 16503867
Apolipoprotein A-I(Milano): current perspectives.
Chiesa G, Sirtori CR
Curr Opin Lipidol 2003 Apr;14(2):159-63. doi: 10.1097/00041433-200304000-00007. PMID: 12642784

Prognosis

Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.
Kazi D, Farmer JA
Curr Atheroscler Rep 2005 Mar;7(2):88-94. doi: 10.1007/s11883-005-0029-x. PMID: 15727722
Molecular characterization of native and recombinant apolipoprotein A-IMilano dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I.
Calabresi L, Vecchio G, Longhi R, Gianazza E, Palm G, Wadensten H, Hammarström A, Olsson A, Karlström A, Sejlitz T
J Biol Chem 1994 Dec 23;269(51):32168-74. PMID: 7798214

Clinical prediction guides

A Compendium of the Biological Effects of Apolipoprotein A-I(Milano).
Parolini C
J Pharmacol Exp Ther 2020 Jan;372(1):54-62. Epub 2019 Oct 24 doi: 10.1124/jpet.119.261719. PMID: 31649050
Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial.
Nicholls SJ, Puri R, Ballantyne CM, Jukema JW, Kastelein JJP, Koenig W, Wright RS, Kallend D, Wijngaard P, Borgman M, Wolski K, Nissen SE
JAMA Cardiol 2018 Sep 1;3(9):806-814. doi: 10.1001/jamacardio.2018.2112. PMID: 30046837Free PMC Article
MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216.
Reijers JAA, Kallend DG, Malone KE, Jukema JW, Wijngaard PLJ, Burggraaf J, Moerland M
Cardiovasc Drugs Ther 2017 Aug;31(4):381-389. doi: 10.1007/s10557-017-6746-x. PMID: 28844118Free PMC Article
ApoA-I Milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progression.
Kaul S, Shah PK
Curr Drug Targets Cardiovasc Haematol Disord 2005 Dec;5(6):471-9. doi: 10.2174/156800605774962004. PMID: 16503867
Apolipoprotein A-I and the molecular variant apoA-I(Milano): evaluation of the antiatherogenic effects in knock-in mouse model.
Parolini C, Chiesa G, Gong E, Caligari S, Cortese MM, Koga T, Forte TM, Rubin EM
Atherosclerosis 2005 Dec;183(2):222-9. Epub 2005 Apr 21 doi: 10.1016/j.atherosclerosis.2005.03.008. PMID: 16285990

Recent systematic reviews

Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials.
Kühnast S, Fiocco M, van der Hoorn JW, Princen HM, Jukema JW
Eur J Pharmacol 2015 Sep 15;763(Pt A):48-63. Epub 2015 May 16 doi: 10.1016/j.ejphar.2015.03.089. PMID: 25989133

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...